View

The Study

Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.

In simple terms

This study is like a computer game that predicts what might happen if people took a drug, but no real people were actually studied. It can show possible outcomes based on guesses, but it can't prove what really happens in real life.

0%

Analysis score

0/ 0

Maximum 0 for a computational/algorithm study.

Where the score came from

Reporting0
Methodology13
Publication100
Statistical0
Study type (basis of the score)
Computational/Algorithm Study
Level 5 - Expert opinion
What’s the bottom line?

Scientists used a computer model to see if giving semaglutide to people who are overweight and have heart disease (but not diabetes) is worth the cost over their lifetime.

Where does this study sit?

Reviews of RCTs (Meta-analyses)

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Expert Opinion
Level 5
0

0 / 100

Quality score

Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.

Cannot establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1The result suggests semaglutide could be worth the cost if priced lower, especially for people with heart disease and obesity.
  2. 2Semaglutide costs $72,962 for each extra year of healthy life.
  3. 3If the price drops by half, it costs $37,190 per extra healthy year.
  4. 4At the lower price, there's an 80% chance it's a good use of healthcare money.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

The Canadian journal of cardiology

Year

2025

Authors

Elissa Rennert-May, Braden Manns, F. Clement, E. Spackman, David Collister, G. Sumner, Jenine Leal, R. Miller, Derek S. Chew

Open Access
8 citations
Analysis v5
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.